menu search

KONEF / KetamineOne changes name to Wellbeing Digital Science

KetamineOne changes name to Wellbeing Digital Science
KetamineOne Capital Limited (LSE:CAPD) announced that the company will change its name to Wellbeing Digital Science Inc.  Wellbeing will continue to trade under the stock symbol ‘MEDI' on the NEO Exchange, under the stock symbol ‘KONEF' on the OTCQB Venture Market and under the symbol ‘MY0' on the Frankfurt Stock Exchange. “We are excited to announce our new name and reveal our updated branding that is better aligned with our multidisciplinary approach, which encompasses mental and physical health through the pursuit of a variety of traditional and novel digital therapeutics,” said Adam Deffett, interim CEO of Wellbeing. Read More
Posted: Jan 24 2022, 08:54
Author Name: Proactive Investors
Views: 110528

KONEF News  

Wellbeing Digital Sciences enters deal to sell KGK Science stake to Cardinal Group

By Proactive Investors
June 19, 2023

Wellbeing Digital Sciences enters deal to sell KGK Science stake to Cardinal Group

Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) told investors it has struck a deal to sell its wholly-owned KGK Science subsidiary to Card more_horizontal

Wellbeing Digital Sciences subsidiary KGK Science starts patient recruitment for psilocybin and fragile X syndrome trial

By Proactive Investors
April 18, 2023

Wellbeing Digital Sciences subsidiary KGK Science starts patient recruitment for psilocybin and fragile X syndrome trial

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) reported that its subsidiary KGK Science on behalf of its client Nova Mentis has commenced pati more_horizontal

Wellbeing Digital Sciences says KGK subsidiary applies for Controlled Substance Dealers License; receives approval for research facility buildout

By Proactive Investors
March 8, 2023

Wellbeing Digital Sciences says KGK subsidiary applies for Controlled Substance Dealers License; receives approval for research facility buildout

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned KGK Sciences Inc (KGK) subsidiary has applied for a Controlled more_horizontal

Wellbeing Digital Sciences caffeine replacement product boosted by preclinical study

By Proactive Investors
February 15, 2023

Wellbeing Digital Sciences caffeine replacement product boosted by preclinical study

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) told investors its subsidiary KGK Science Inc (KGK) has completed preclinical safety studies fo more_horizontal

Wellbeing Digital Sciences says KGK subsidiary receives exemption to begin psilocybin clinical trial

By Proactive Investors
February 14, 2023

Wellbeing Digital Sciences says KGK subsidiary receives exemption to begin psilocybin clinical trial

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) said its wholly-owned subsidiary KGK Sciences Inc. has received an exemption under Section 56 more_horizontal

Wellbeing Digital Sciences says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome

By Proactive Investors
December 23, 2022

Wellbeing Digital Sciences says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome

Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection le more_horizontal

Wellbeing Digital Sciences subsidiary KGK Science awarded cannabis research license

By Proactive Investors
December 8, 2022

Wellbeing Digital Sciences subsidiary KGK Science awarded cannabis research license

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly owned subsidiary KGK Science Inc has been awarded an institution-wide canna more_horizontal

Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response

By Proactive Investors
December 6, 2022

Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that a clinical study conducted by wholly-owned subsidiary KGK Science Inc has shown more_horizontal


Search within

Pages Search Results: